Skip to main content
QSI
NASDAQ Industrial Applications And Services

Proteus Platform Reaches 19 Amino Acids, Closing In on Full 20-Amino-Acid Detection

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.227
Mkt Cap
$267.038M
52W Low
$0.69
52W High
$3.1
52W Position info
78% above low
Off High info
60% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

QSI sits 78% above its 52-week low of $0.69.

Summary

Quantum-Si announced detection of 19 amino acids in its Proteus development program, up from 18, and reaffirmed confidence in detecting all 20 amino acids by year-end 2026.


Key Events · Product Development and Regulatory · QSI

  • 19 Amino Acids Detected

    The Proteus development program has now demonstrated detection of 19 amino acids, an increase from the 18 amino acids shown at World HUPO 2026.

  • Deployment into Sequencing Kit

    Work is underway to deploy the 19-amino-acid capability into a developmental sequencing kit for routine use on integrated Proteus instruments.

  • 20-Amino-Acid Goal Reaffirmed

    Management stated growing confidence in demonstrating detection of all 20 amino acids by year-end 2026, with commercial launch of Proteus targeted for Q2 2027.

  • Distressed Financial Backdrop

    The milestone follows Q2 revenue of $344,000, a 20% workforce reduction, and a Nasdaq delisting notice, making Proteus progress critical to the company's survival.


Analysis · QSI · Industrial Applications And Services

Advancing its Proteus protein sequencing platform from 18 to 19 detectable amino acids marks a concrete technical milestone for Quantum-Si, supporting the company's stated goal of detecting all 20 amino acids by year-end 2026. This progress matters because Proteus is the company's core growth driver, with commercial launch targeted for Q2 2027. The announcement comes against a backdrop of severe financial distress — Q2 revenue of only $344,000, a 20% workforce reduction, and a Nasdaq delisting notice — so any evidence that the flagship product is progressing toward launch is material to the investment thesis. The company is now working to deploy the 19-amino-acid capability into a developmental sequencing kit, which management expects will further improve sequencing performance.

How filings like this one have moved

In the 30 days to Oct 8, 2026, 28.6% of the 1679 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, QSI was trading at $1.23 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $267M. The 52-week trading range was $0.69 to $3.10. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

QSI - Latest Insights

QSI
Sep 28, 2026, 8:29 PM EDT
Filing Type: 8-K
Importance Score:
7
QSI
Sep 28, 2026, 8:15 PM EDT
Source: GlobeNewswire
Importance Score:
7
QSI
Aug 28, 2026, 5:35 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
QSI
Aug 13, 2026, 4:55 PM EDT
Filing Type: 10-Q
Importance Score:
8
QSI
Aug 13, 2026, 4:23 PM EDT
Source: Reuters
Importance Score:
8